Programmed death-ligand 1 expression according to epidermal growth factor receptor mutation status in pretreated non-small cell lung cancer.
| Author | |
|---|---|
| Abstract |
:
Current clinical trials have suggested poorer efficacies of anti-programmed death-1 (PD-1)/PD-ligand 1 (PD-L1) immunotherapies for non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations, implying lower PD-L1 expression in EGFR-mutant NSCLC than in EGFR-wild type. |
| Year of Publication |
:
2017
|
| Journal |
:
Oncotarget
|
| Volume |
:
8
|
| Issue |
:
69
|
| Number of Pages |
:
113807-113816
|
| Date Published |
:
2017
|
| DOI |
:
10.18632/oncotarget.22837
|
| Short Title |
:
Oncotarget
|
| Download citation |
